Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration has approved
NOXAFIL (posaconazole) injection (18 mg/ mL), a new
formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal
agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and
NOXAFIL (40 mg/mL) oral suspension.
Language:
English
Contact:
MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more